News

Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has filed a pre-Investigational New

The FDA approval allows Qinlock, a kinase inhibitor, to treat adult patients with advanced GIST who have secured prior treatment with three or more kinase inhibitors, including imatinib.

Four metastatic pancreatic cancer patients have been treated with PD-L1 t-haNK and N-803 under single patient INDs, with two patients on treatment for an evaluable period. One patient reported

FDA Fast Track is a program designed to facilitate and expedite the development and review of a new drugs that demonstrates the potential to address an unmet medical

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE)

This agreement is part of Cipla’s efforts to enhance global access to life-saving treatments for patients affected by the pandemic. As part of the agreement, Cipla will be

GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise

As per terms of the deal, Catalent will involve in the development of a powder-in-capsule formulation for Ennaid’s ENU200 programme. Ennaid’s ENU200 is a patent-pending and repurposed oral

The application for TUKYSA approval was reviewed by Swissmedic as part of Project Orbis, an initiative of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence